The Netherlands Cancer Institute clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 230 studies whose lead sponsor is The Netherlands Cancer Institute. 66 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the The Netherlands Cancer Institute studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions The Netherlands Cancer Institute leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 230. Browse all 230 →
- Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung CancerRecruitingNCT07436858Phase 1
- TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast CancerRecruitingNCT06931769
- RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung CancerNot yet recruitingNCT07808138Phase 2
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingNCT03026140Phase 2
- Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast CancerRecruitingNCT06362616Not applicable
- COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO StudyRecruitingNCT05301881Phase 2
- DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)Not yet recruitingNCT07786051Phase 2
- Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTRecruitingNCT06222489Phase 2
- Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain MetastasesRecruitingNCT07511933Not applicable
- Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain MetastasesRecruitingNCT06888817Phase 3
- LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsRecruitingNCT06012734Phase 1
- Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingNCT07663747Phase 2
- Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational StudyRecruitingNCT07522762
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingNCT07460180Phase 1/2
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsRecruitingNCT06279130Phase 2/3
- Short Course of Radiotherapy Prior to Surgery of Soft Tissue SarcomasRecruitingNCT07071727Not applicable
- Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two FractionsRecruitingNCT07391982Not applicable
- Contrast-enhanced Ultrasound for Sentinel Node DetectionRecruitingNCT07310758Phase 2/3
- Transtympanic STS Against Cisplatin-induced SNHL: the SOUND TrialRecruitingNCT07281508Phase 3
- Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerRecruitingNCT06353906Phase 2
- Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer PatientsRecruitingNCT06273800Not applicable
- Basket Study for Oligo-metastatic Breast CancerRecruitingNCT05982678Phase 2
- Functional Liver After SBRTRecruitingNCT07033364
- Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal CancerRecruitingNCT06568679
- Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)RecruitingNCT06691776Not applicable
- The Radium-select StudyRecruitingNCT06659926Not applicable
- Towards Cure Via Only Ultra-short ICB in CSCCRecruitingNCT06823479Phase 2
- OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating LymphocytesRecruitingNCT06476119
- DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic TherapyRecruitingNCT05416164Not applicable
- PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)RecruitingNCT06875258Phase 4
- FMT to Convert Response to ImmunotherapyRecruitingNCT05251389Phase 1/2
- Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic TherapyRecruitingNCT06857773Phase 3
- Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA TrialRecruitingNCT06855095Phase 2/3
- Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMERRecruitingNCT06528743Not applicable
- Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2
- The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate CancerNot yet recruitingNCT06634173Not applicable
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingNCT06342037Phase 2
- A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)RecruitingNCT02910895Not applicable
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingNCT03815890Phase 2
- Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVCRecruitingNCT05905315Phase 2
- Distributed Learning of Edic and CardIac Dose Effects in Lung CancerNot yet recruitingNCT06329648
- The MR-Linac Technical Feasibility ProtocolRecruitingNCT04351204Not applicable
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1
- Peri-operative Slow-paced Breathing to Reduce Anxiety in Breast Cancer Surgery PatientsRecruitingNCT06192225Not applicable
- Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer PatientsRecruitingNCT06142344Not applicable
- Image-guided Navigation During Robotic Sentinel Node RemovalRecruitingNCT06091072Not applicable
- Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.RecruitingNCT04737382Not applicable
- Tracer-Guided Surgery for Recurrent Prostate CancerRecruitingNCT05555017Phase 2